CSO sells 386,240 Adaptive Biotechnologies (NASDAQ: ADPT) shares under plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of 386,240 shares of common stock on July 2, 2026. The sales occurred in two blocks at weighted-average prices of $21.74 and $22.45 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were scheduled in advance rather than timed discretionarily. After these sales, he continues to hold a significant direct equity position in the company.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 386,240 shares ($8,501,149)
Net Sell
2 txns
Insider
ROBINS HARLAN S
Role
Chief Scientific Officer
Sold
386,240 shs ($8.50M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 239,351 | $21.74 | $5.20M |
| Sale | Common Stock | 146,889 | $22.45 | $3.30M |
Holdings After Transaction:
Common Stock — 1,166,547 shares (Direct, null)
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.15 to $22.145, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.15 to $22.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Key Figures
Total shares sold: 386,240 shares
First block sold: 146,889 shares at $22.45
Second block sold: 239,351 shares at $21.74
+2 more
5 metrics
Total shares sold
386,240 shares
Open-market sales on July 2, 2026
First block sold
146,889 shares at $22.45
Common stock, open-market sale
Second block sold
239,351 shares at $21.74
Common stock, open-market sale
Net share change
-386,240 shares
Net buy/sell direction reported as net-sell
Rule 10b5-1 plan adoption date
March 13, 2026
Plan governing the reported trades
Key Terms
Rule 10b5-1 trading plan, weighted-average price, open-market sale, Form 4
4 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions..."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
open-market sale financial
"transaction_action: "open-market sale", transaction_code_description: "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transactions did Adaptive Biotechnologies (ADPT) report for Harlan S. Robins?
Adaptive Biotechnologies reported that Chief Scientific Officer Harlan S. Robins sold 386,240 shares of common stock in two open-market transactions on July 2, 2026, at weighted-average prices of $21.74 and $22.45 per share, according to a Form 4 filing.
Were the Adaptive Biotechnologies (ADPT) insider sales pre-planned under Rule 10b5-1?
Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Harlan S. Robins on March 13, 2026. Such pre-planned programs schedule trades in advance, reducing the significance of short-term market timing.
Who is the insider involved in the recent Adaptive Biotechnologies (ADPT) Form 4 filing?
The insider is Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp. The Form 4 indicates he holds the position of officer and completed the reported common stock sales in his capacity as a direct shareholder in the company.